Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Liliane Hobeika, Sally E Self, Juan Carlos Q Velez

ABSTRACT

BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. More... »

PAGES

156

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2369-15-156

DOI

http://dx.doi.org/10.1186/1471-2369-15-156

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047232947

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25267524


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Kidney Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boronic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Edema", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatal Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension, Renal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lenalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Podocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteinuria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Shock, Septic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Teniposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombotic Microangiopathies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobeika", 
        "givenName": "Liliane", 
        "id": "sg:person.01027631644.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Department of Pathology, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Self", 
        "givenName": "Sally E", 
        "id": "sg:person.015017370564.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Velez", 
        "givenName": "Juan Carlos Q", 
        "id": "sg:person.01131201727.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190802023707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009669974"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bcr-2012-006461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011174364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076", 
          "https://doi.org/10.1046/j.1523-1755.2003.00071.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3346/jkms.2014.29.5.648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013160147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semnephrol.2010.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019546282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ki.5000055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020678317", 
          "https://doi.org/10.1038/sj.ki.5000055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beha.2007.09.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025914764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-15-107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026028815", 
          "https://doi.org/10.1186/1745-6215-15-107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/gft465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028765304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/qjmed/89.10.751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031036405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/petr.12300", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033543085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.humpath.2014.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1445-5994.2011.02458.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035735607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2215/cjn.02070508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038375943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1981.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040267576", 
          "https://doi.org/10.1038/clpt.1981.154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047843351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1702849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050017834", 
          "https://doi.org/10.1038/sj.bmt.1702849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci115629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050923946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.atv.17.11.2793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063334494"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079879530", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.\nCASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 \u03bcmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later.\nCONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2369-15-156", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024626", 
        "issn": [
          "1471-2369"
        ], 
        "name": "BMC Nephrology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma", 
    "pagination": "156", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25267524"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967793"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2369-15-156"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047232947"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2369-15-156", 
      "https://app.dimensions.ai/details/publication/pub.1047232947"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54316_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2F1471-2369-15-156"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      86 URIs      49 LITERALS      37 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2369-15-156 schema:about N04db88cb59de4982a594bbc1de86b13f
2 N1e073a5f8fe1426c8e400f9ffa6cc3ec
3 N266b0f53eb0d418fa7eb085e1ea9c41d
4 N284299d6d83348598617005c199042ee
5 N37b7d16a70e6410b8083a48f410d8ff5
6 N3805c188b55a4379b8ee523dd989fb11
7 N3c190e9bf6364f35891458646c399dac
8 N49466459aafe4bbe8c54175a08eb58ba
9 N52842683f78f4624a317282e1b07cbcd
10 N54c4b651feb44886b497f99b3b07e70e
11 N56b5144873544b36a6a17d204529342f
12 N5904b23a22d746ae93a19ca6f7cf59ef
13 N5c5dea693308475881382cbb2ad4834b
14 N614065fdc3ae4c8695380247588acf41
15 N63035f0c8e484a038e28794b3198b8f6
16 N682099d1178845b8a40bfc439a729b2b
17 N682ce08b60a24a4482cc924128f72ef1
18 N882d7554c1814c3d9334eb2a9cc96459
19 Na7e437d3cca6413c8918ce26357ae4f2
20 Nabdbfe5e74fc439a8d13309bda6bdf6d
21 Nafc8df68a45849aca4375130a20c43ba
22 Nced04c7c09fa4fe9bbd03078aba5e075
23 Ndaa57a6d1a2846dda91e240d22f83cad
24 Ne8cce892f9ce4bdf91ed5d6049776b56
25 Nf1928075b4df46eda993dfb951035ee4
26 Nf664aa56536b4977b2a37de2555a1f22
27 Nf78cd58b48ac4bd2b5e264c16aa6a943
28 Nf81124ad49a047ddb0ee3cf4e131eed7
29 anzsrc-for:11
30 anzsrc-for:1103
31 schema:author N65029e05e6a54871a50bdb93eb2a3820
32 schema:citation sg:pub.10.1007/s12185-008-0140-1
33 sg:pub.10.1038/clpt.1981.154
34 sg:pub.10.1038/nrc780
35 sg:pub.10.1038/sj.bmt.1700791
36 sg:pub.10.1038/sj.bmt.1701171
37 sg:pub.10.1038/sj.bmt.1701830
38 sg:pub.10.1038/sj.bmt.1702849
39 sg:pub.10.1038/sj.ki.5000055
40 sg:pub.10.1046/j.1523-1755.2003.00071.x
41 sg:pub.10.1186/1745-6215-15-107
42 https://app.dimensions.ai/details/publication/pub.1079879530
43 https://doi.org/10.1016/j.beha.2007.09.003
44 https://doi.org/10.1016/j.humpath.2014.05.015
45 https://doi.org/10.1016/j.semnephrol.2010.09.007
46 https://doi.org/10.1046/j.1523-1755.2003.00071.x
47 https://doi.org/10.1056/nejmoa0707330
48 https://doi.org/10.1080/10428190802023707
49 https://doi.org/10.1093/ndt/gft465
50 https://doi.org/10.1093/qjmed/89.10.751
51 https://doi.org/10.1111/j.1445-5994.2011.02458.x
52 https://doi.org/10.1111/petr.12300
53 https://doi.org/10.1136/bcr-2012-006461
54 https://doi.org/10.1158/0008-5472.can-06-4086
55 https://doi.org/10.1161/01.atv.17.11.2793
56 https://doi.org/10.1172/jci115629
57 https://doi.org/10.2215/cjn.02070508
58 https://doi.org/10.3346/jkms.2014.29.5.648
59 https://doi.org/10.4081/hr.2012.e13
60 https://doi.org/10.4143/crt.2008.40.4.211
61 schema:datePublished 2014-12
62 schema:datePublishedReg 2014-12-01
63 schema:description BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
64 schema:genre research_article
65 schema:inLanguage en
66 schema:isAccessibleForFree true
67 schema:isPartOf N02aa11144a2b45dc85067d4e4a2c0fb2
68 Nbb124c34b3a247aa9c6babd9cb6721e8
69 sg:journal.1024626
70 schema:name Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
71 schema:pagination 156
72 schema:productId N0e0f7db97f084a3f976430df7940e243
73 N354ddb5f1748425b9c427faa66958544
74 N4a384b5ce3e64ef8a823eceeccf534ca
75 N71af8b8de8e44817bd0d2a425c2f8031
76 Na2c773c013464271932d67c9affc42b4
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047232947
78 https://doi.org/10.1186/1471-2369-15-156
79 schema:sdDatePublished 2019-04-11T10:18
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N2f002cdd7aa949c39d64360bbf8aa2e4
82 schema:url https://link.springer.com/10.1186%2F1471-2369-15-156
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N02aa11144a2b45dc85067d4e4a2c0fb2 schema:volumeNumber 15
87 rdf:type schema:PublicationVolume
88 N04db88cb59de4982a594bbc1de86b13f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Acute Kidney Injury
90 rdf:type schema:DefinedTerm
91 N0e0f7db97f084a3f976430df7940e243 schema:name dimensions_id
92 schema:value pub.1047232947
93 rdf:type schema:PropertyValue
94 N1e073a5f8fe1426c8e400f9ffa6cc3ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Thrombotic Microangiopathies
96 rdf:type schema:DefinedTerm
97 N266b0f53eb0d418fa7eb085e1ea9c41d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Antineoplastic Combined Chemotherapy Protocols
99 rdf:type schema:DefinedTerm
100 N284299d6d83348598617005c199042ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Antineoplastic Agents
102 rdf:type schema:DefinedTerm
103 N2f002cdd7aa949c39d64360bbf8aa2e4 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N354ddb5f1748425b9c427faa66958544 schema:name doi
106 schema:value 10.1186/1471-2369-15-156
107 rdf:type schema:PropertyValue
108 N37b7d16a70e6410b8083a48f410d8ff5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Boronic Acids
110 rdf:type schema:DefinedTerm
111 N3805c188b55a4379b8ee523dd989fb11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Teniposide
113 rdf:type schema:DefinedTerm
114 N3c190e9bf6364f35891458646c399dac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Recurrence
116 rdf:type schema:DefinedTerm
117 N49466459aafe4bbe8c54175a08eb58ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Hypertension, Renal
119 rdf:type schema:DefinedTerm
120 N4a384b5ce3e64ef8a823eceeccf534ca schema:name pubmed_id
121 schema:value 25267524
122 rdf:type schema:PropertyValue
123 N52842683f78f4624a317282e1b07cbcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Fatal Outcome
125 rdf:type schema:DefinedTerm
126 N54c4b651feb44886b497f99b3b07e70e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Edema
128 rdf:type schema:DefinedTerm
129 N56b5144873544b36a6a17d204529342f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Hematopoietic Stem Cell Transplantation
131 rdf:type schema:DefinedTerm
132 N5904b23a22d746ae93a19ca6f7cf59ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Pyrazines
134 rdf:type schema:DefinedTerm
135 N5c5dea693308475881382cbb2ad4834b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Proteinuria
137 rdf:type schema:DefinedTerm
138 N614065fdc3ae4c8695380247588acf41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Proteasome Inhibitors
140 rdf:type schema:DefinedTerm
141 N63035f0c8e484a038e28794b3198b8f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Disease Progression
143 rdf:type schema:DefinedTerm
144 N65029e05e6a54871a50bdb93eb2a3820 rdf:first sg:person.01027631644.51
145 rdf:rest Nc0706cb4755c41aeaf736515a88519c5
146 N682099d1178845b8a40bfc439a729b2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 N682ce08b60a24a4482cc924128f72ef1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Shock, Septic
151 rdf:type schema:DefinedTerm
152 N71af8b8de8e44817bd0d2a425c2f8031 schema:name readcube_id
153 schema:value e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d
154 rdf:type schema:PropertyValue
155 N882d7554c1814c3d9334eb2a9cc96459 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Lenalidomide
157 rdf:type schema:DefinedTerm
158 Na2c773c013464271932d67c9affc42b4 schema:name nlm_unique_id
159 schema:value 100967793
160 rdf:type schema:PropertyValue
161 Na7e437d3cca6413c8918ce26357ae4f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Multiple Myeloma
163 rdf:type schema:DefinedTerm
164 Nabdbfe5e74fc439a8d13309bda6bdf6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 Nae3c9466baaa473e974752a93d23b4a0 rdf:first sg:person.01131201727.91
168 rdf:rest rdf:nil
169 Nafc8df68a45849aca4375130a20c43ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Podocytes
171 rdf:type schema:DefinedTerm
172 Nbb124c34b3a247aa9c6babd9cb6721e8 schema:issueNumber 1
173 rdf:type schema:PublicationIssue
174 Nc0706cb4755c41aeaf736515a88519c5 rdf:first sg:person.015017370564.33
175 rdf:rest Nae3c9466baaa473e974752a93d23b4a0
176 Nced04c7c09fa4fe9bbd03078aba5e075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Thalidomide
178 rdf:type schema:DefinedTerm
179 Ndaa57a6d1a2846dda91e240d22f83cad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Dexamethasone
181 rdf:type schema:DefinedTerm
182 Ne8cce892f9ce4bdf91ed5d6049776b56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Bortezomib
184 rdf:type schema:DefinedTerm
185 Nf1928075b4df46eda993dfb951035ee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Combined Modality Therapy
187 rdf:type schema:DefinedTerm
188 Nf664aa56536b4977b2a37de2555a1f22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Oligopeptides
190 rdf:type schema:DefinedTerm
191 Nf78cd58b48ac4bd2b5e264c16aa6a943 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Middle Aged
193 rdf:type schema:DefinedTerm
194 Nf81124ad49a047ddb0ee3cf4e131eed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Cyclophosphamide
196 rdf:type schema:DefinedTerm
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1024626 schema:issn 1471-2369
204 schema:name BMC Nephrology
205 rdf:type schema:Periodical
206 sg:person.01027631644.51 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
207 schema:familyName Hobeika
208 schema:givenName Liliane
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51
210 rdf:type schema:Person
211 sg:person.01131201727.91 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
212 schema:familyName Velez
213 schema:givenName Juan Carlos Q
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91
215 rdf:type schema:Person
216 sg:person.015017370564.33 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
217 schema:familyName Self
218 schema:givenName Sally E
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33
220 rdf:type schema:Person
221 sg:pub.10.1007/s12185-008-0140-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032870534
222 https://doi.org/10.1007/s12185-008-0140-1
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/clpt.1981.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040267576
225 https://doi.org/10.1038/clpt.1981.154
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrc780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024581782
228 https://doi.org/10.1038/nrc780
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/sj.bmt.1700791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038194035
231 https://doi.org/10.1038/sj.bmt.1700791
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bmt.1701171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006660654
234 https://doi.org/10.1038/sj.bmt.1701171
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.bmt.1701830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037910558
237 https://doi.org/10.1038/sj.bmt.1701830
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/sj.bmt.1702849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050017834
240 https://doi.org/10.1038/sj.bmt.1702849
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/sj.ki.5000055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020678317
243 https://doi.org/10.1038/sj.ki.5000055
244 rdf:type schema:CreativeWork
245 sg:pub.10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
246 https://doi.org/10.1046/j.1523-1755.2003.00071.x
247 rdf:type schema:CreativeWork
248 sg:pub.10.1186/1745-6215-15-107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026028815
249 https://doi.org/10.1186/1745-6215-15-107
250 rdf:type schema:CreativeWork
251 https://app.dimensions.ai/details/publication/pub.1079879530 schema:CreativeWork
252 https://doi.org/10.1016/j.beha.2007.09.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025914764
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.humpath.2014.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034050093
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/j.semnephrol.2010.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019546282
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1056/nejmoa0707330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840499
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1080/10428190802023707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009669974
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1093/ndt/gft465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028765304
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1093/qjmed/89.10.751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031036405
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1111/j.1445-5994.2011.02458.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035735607
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1111/petr.12300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033543085
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1136/bcr-2012-006461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011174364
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1158/0008-5472.can-06-4086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047843351
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.atv.17.11.2793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063334494
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1172/jci115629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050923946
279 rdf:type schema:CreativeWork
280 https://doi.org/10.2215/cjn.02070508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038375943
281 rdf:type schema:CreativeWork
282 https://doi.org/10.3346/jkms.2014.29.5.648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013160147
283 rdf:type schema:CreativeWork
284 https://doi.org/10.4081/hr.2012.e13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028803821
285 rdf:type schema:CreativeWork
286 https://doi.org/10.4143/crt.2008.40.4.211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072255766
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.259828.c schema:alternateName Medical University of South Carolina
289 schema:name Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
290 Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
291 rdf:type schema:Organization
292 https://www.grid.ac/institutes/grid.266623.5 schema:alternateName University of Louisville
293 schema:name Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...